“The surge continues in pharmaceutical services” – C&EN report features Sai Life Sciences

The Chemical & Engineering News, arguably the world's most comprehensive and authoritative news source about chemistry and related fields, featured Sai Life Sciences in its report covering CPhI Worldwide 2019.
Observing the recent trend of contract manufacturing and development firms making transformative investments in their capabilities, C&EN takes the example of Sai Life Sciences, which is investing US $150 Mn in an unprecedented scale up of its facilities. Here’s an extract from the article:

“Another Indian company, Hyderabad-based Sai Life Sciences, is experiencing a growth surge with a near doubling of capacity this year and plans to boost it another 35% by mid-2021, according to CEO Krishna Kanumuri. The majority-family-owned firm also wants to double discovery services capacity in the next 12 months.
Investments are planned at labs in Manchester, England, and Cambridge, Massachusetts, and the firm is building a new research facility at its headquarters that will house 1,500 scientists when complete. Sai will invest $150 million between 2019 and 2023, Kanumuri said.
Behind the surge: “It’s just that our customers have grown,” he said. “We have helped along several companies that have launched molecules commercially over the last 5 years. You start slow, but once you establish yourself, the rate of growth goes up, and that’s where we are at this point.”